RxDoctor Payments Data

Kathleen Ulivi

Family · Gardner, ILNPI 1619219110

Payments from drug & device makers

$692in general payments, 2019–2025

Across 20 payments — averaging $34.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$327
  • Novo Nordisk$249
  • Abbott$53
  • AbbVie$21
  • Lilly USA, LLC$15
  • Nestle Healthcare Nutrition Inc.$15
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$67698%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$692 in reported general payments places this provider in the 65th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$32,449
Medicare patients
187
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide16$32,983
JanuviaSitagliptin Phosphate13$22,012
JardianceEmpagliflozin17$17,039
OzempicSemaglutide14$14,073
EliquisApixaban12$7,317
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,776
Metoprolol Succinate87$1,934
Atorvastatin Calcium186$1,699
Levothyroxine Sodium149$1,609
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,395
Albuterol Sulfate HfaAlbuterol Sulfate62$1,327
Escitalopram Oxalate77$1,223
Lisinopril132$1,139
Losartan Potassium86$1,003
Duloxetine Hcl40$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$249$47,05630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,941 family providers in Illinois.

Other family in Gardner

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →